PHARMACOGENOMICS MARKET ANALYSIS

Pharmacogenomics Market, By Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and Others), By Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Pain Management, and Others), By End User (Hospitals & Clinics, Research Institutions and Academic Institutes, Diagnostic Laboratories, and Others) By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On February 26, 2024, Golden Helix, Inc., a bioinformatics company, launched of VSPGx, a pharmacogenomics solution for hospitals and testing labs
In May 2023, University of California, San Francisco (UCSF), a health science university, announced that they had launched first pharmacogenomics testing service in California, the health care delivered to patients at UCSF Health will be systematically informed by patient genomic data, ensuring that prescribed therapies are tailored to individuals’ unique biology
In December 2022, MapMyGenome, a preventive genomics company, announced that it had launched MedicaMap, pharmacogenomics solution that analyses an individual's response to medicines, based on genetic makeup
In May 2022, Invitae Corporation, a medical genetics company, announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx) Panel which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST)